Literature DB >> 25327211

Interleukin-22 and CD160 play additive roles in the host mucosal response to Clostridium difficile infection in mice.

Amir A Sadighi Akha1, Andrew J McDermott, Casey M Theriot, Paul E Carlson, Charles R Frank, Roderick A McDonald, Nicole R Falkowski, Ingrid L Bergin, Vincent B Young, Gary B Huffnagle.   

Abstract

Our previous work has shown the significant up-regulation of Il22 and increased phosphorylation of signal transducer and activator of transcription 3 (STAT3) as part of the mucosal inflammatory response to Clostridium difficile infection in mice. Others have shown that phosphorylation of STAT3 at mucosal surfaces includes interleukin-22 (IL-22) and CD160-mediated components. The current study sought to determine the potential role(s) of IL-22 and/or CD160 in the mucosal response to C. difficile infection. Clostridium difficile-infected mice treated with anti-IL-22, anti-CD160 or a combination of the two showed significantly reduced STAT3 phosphorylation in comparison to C. difficile-infected mice that had not received either antibody. In addition, C. difficile-infected mice treated with anti-IL-22/CD160 induced a smaller set of genes, and at significantly lower levels than the untreated C. difficile-infected mice. The affected genes included pro-inflammatory chemokines and cytokines, and anti-microbial peptides. Furthermore, histopathological and flow cytometric assessments both showed a significantly reduced influx of neutrophils in C. difficile-infected mice treated with anti-IL-22/CD160. These data demonstrate that IL-22 and CD160 are together responsible for a significant fraction of the colonic STAT3 phosphorylation in C. difficile infection. They also underscore the additive effects of IL-22 and CD160 in mediating both the pro-inflammatory and pro-survival aspects of the host mucosal response in this infection.
© 2014 John Wiley & Sons Ltd.

Entities:  

Keywords:  CD160; Clostridium difficile; RegIIIγ; interleukin-22; pSTAT3

Mesh:

Substances:

Year:  2015        PMID: 25327211      PMCID: PMC4368165          DOI: 10.1111/imm.12414

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  55 in total

Review 1.  Interleukin-25 negatively controls pathogenic responses in the gut.

Authors:  Eleonora Franzè; Angelamaria Rizzo; Roberta Caruso; Francesco Pallone; Giovanni Monteleone
Journal:  Inflamm Allergy Drug Targets       Date:  2011-06

2.  Clospore: a liquid medium for producing high titers of semi-purified spores of Clostridium difficile.

Authors:  Justo Perez; V Susan Springthorpe; Syed A Sattar
Journal:  J AOAC Int       Date:  2011 Mar-Apr       Impact factor: 1.913

3.  Points of significance: Comparing samples—part I.

Authors:  Martin Krzywinski; Naomi Altman
Journal:  Nat Methods       Date:  2014-03       Impact factor: 28.547

4.  Nucleotide-binding oligomerization domain 1 mediates recognition of Clostridium difficile and induces neutrophil recruitment and protection against the pathogen.

Authors:  Mizuho Hasegawa; Takashi Yamazaki; Nobuhiko Kamada; Kazuki Tawaratsumida; Yun-Gi Kim; Gabriel Núñez; Naohiro Inohara
Journal:  J Immunol       Date:  2011-03-16       Impact factor: 5.422

Review 5.  Border patrol: regulation of immunity, inflammation and tissue homeostasis at barrier surfaces by IL-22.

Authors:  Gregory F Sonnenberg; Lynette A Fouser; David Artis
Journal:  Nat Immunol       Date:  2011-05       Impact factor: 25.606

6.  Toll-like receptor 5 stimulation protects mice from acute Clostridium difficile colitis.

Authors:  Irene Jarchum; Mingyu Liu; Lauren Lipuma; Eric G Pamer
Journal:  Infect Immun       Date:  2011-01-18       Impact factor: 3.441

Review 7.  Microbiota-mediated colonization resistance against intestinal pathogens.

Authors:  Charlie G Buffie; Eric G Pamer
Journal:  Nat Rev Immunol       Date:  2013-10-07       Impact factor: 53.106

8.  HVEM signalling promotes colitis.

Authors:  Corinne Schaer; Stefanie Hiltbrunner; Bettina Ernst; Christoph Mueller; Michael Kurrer; Manfred Kopf; Nicola L Harris
Journal:  PLoS One       Date:  2011-04-18       Impact factor: 3.240

9.  A role for TLR4 in Clostridium difficile infection and the recognition of surface layer proteins.

Authors:  Anthony Ryan; Mark Lynch; Sinead M Smith; Sylvie Amu; Hendrik J Nel; Claire E McCoy; Jennifer K Dowling; Eve Draper; Vincent O'Reilly; Ciara McCarthy; Julie O'Brien; Déirdre Ní Eidhin; Mary J O'Connell; Brian Keogh; Charles O Morton; Thomas R Rogers; Padraic G Fallon; Luke A O'Neill; Dermot Kelleher; Christine E Loscher
Journal:  PLoS Pathog       Date:  2011-06-30       Impact factor: 6.823

10.  Diverse sources of C. difficile infection identified on whole-genome sequencing.

Authors:  Derrick W Crook; Mark H Wilcox; Tim E A Peto; A Sarah Walker; David W Eyre; Madeleine L Cule; Daniel J Wilson; David Griffiths; Alison Vaughan; Lily O'Connor; Camilla L C Ip; Tanya Golubchik; Elizabeth M Batty; John M Finney; David H Wyllie; Xavier Didelot; Paolo Piazza; Rory Bowden; Kate E Dingle; Rosalind M Harding
Journal:  N Engl J Med       Date:  2013-09-26       Impact factor: 91.245

View more
  16 in total

1.  Innate Immune Defenses Mediated by Two ILC Subsets Are Critical for Protection against Acute Clostridium difficile Infection.

Authors:  Michael C Abt; Brittany B Lewis; Silvia Caballero; Huizhong Xiong; Rebecca A Carter; Bože Sušac; Lilan Ling; Ingrid Leiner; Eric G Pamer
Journal:  Cell Host Microbe       Date:  2015-07-08       Impact factor: 21.023

2.  LIGHT-HVEM Signaling in Innate Lymphoid Cell Subsets Protects Against Enteric Bacterial Infection.

Authors:  Goo-Young Seo; Jr-Wen Shui; Daisuke Takahashi; Christina Song; Qingyang Wang; Kenneth Kim; Zbigniew Mikulski; Shilpi Chandra; Daniel A Giles; Sonja Zahner; Pyeung-Hyeun Kim; Hilde Cheroutre; Marco Colonna; Mitchell Kronenberg
Journal:  Cell Host Microbe       Date:  2018-08-08       Impact factor: 21.023

3.  Aging impairs protective host defenses against Clostridioides (Clostridium) difficile infection in mice by suppressing neutrophil and IL-22 mediated immunity.

Authors:  Alex G Peniche; Jennifer K Spinler; Prapaporn Boonma; Tor C Savidge; Sara M Dann
Journal:  Anaerobe       Date:  2018-08-09       Impact factor: 3.331

Review 4.  Type 3 Immunity during Clostridioides difficile Infection: Too Much of a Good Thing?

Authors:  Mahmoud M Saleh; William A Petri
Journal:  Infect Immun       Date:  2019-12-17       Impact factor: 3.441

5.  Role of interferon-γ and inflammatory monocytes in driving colonic inflammation during acute Clostridium difficile infection in mice.

Authors:  Andrew J McDermott; Nicole R Falkowski; Roderick A McDonald; Charles R Frank; Chinmay R Pandit; Vincent B Young; Gary B Huffnagle
Journal:  Immunology       Date:  2017-01-30       Impact factor: 7.397

Review 6.  Role of the leukocyte response in normal and immunocompromised host after Clostridium difficile infection.

Authors:  Edwin Vargas; Senu Apewokin; Rajat Madan
Journal:  Anaerobe       Date:  2017-02-20       Impact factor: 3.331

Review 7.  Clostridium difficile colitis: pathogenesis and host defence.

Authors:  Michael C Abt; Peter T McKenney; Eric G Pamer
Journal:  Nat Rev Microbiol       Date:  2016-08-30       Impact factor: 60.633

Review 8.  Neutrophil-mediated inflammation in the pathogenesis of Clostridium difficile infections.

Authors:  Shinsmon Jose; Rajat Madan
Journal:  Anaerobe       Date:  2016-04-05       Impact factor: 3.331

9.  Interleukin-23 (IL-23), independent of IL-17 and IL-22, drives neutrophil recruitment and innate inflammation during Clostridium difficile colitis in mice.

Authors:  Andrew J McDermott; Nicole R Falkowski; Roderick A McDonald; Chinmay R Pandit; Vincent B Young; Gary B Huffnagle
Journal:  Immunology       Date:  2015-12-02       Impact factor: 7.397

10.  Systemic Inflammatory Responses in Ulcerative Colitis Patients and Clostridium difficile Infection.

Authors:  Julajak Limsrivilai; Krishna Rao; Ryan W Stidham; Shail M Govani; Akbar K Waljee; Andrew Reinink; Laura Johnson; Emily Briggs; Peter D R Higgins
Journal:  Dig Dis Sci       Date:  2018-04-12       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.